Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (APOE) genotype is the major genetic risk factor for Alzheimer disease (AD); the 14 allele increases risk and the 12 allele is protective.In the central nervous system (CNS), apoE is produced by glial cells, is present in high-density-like lipoproteins, interacts with several receptors that are members of the low-density lipoprotein receptor (LDLR) family, and is a protein that binds to the amyloid-b (Ab) peptide.There are a variety of mechanisms by which apoE isoform may influence risk for AD.There is substantial evidence that differential effects of apoE isoform on AD risk are influenced by the ability of apoE to affect Ab aggregation and clearance in the brain.Other mechanisms are also likely to play a role in the ability of apoE to influence CNS function as well as AD, including effects on synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation.ApoE receptors, including LDLRs, Apoer2, very low-density lipoprotein receptors (VLDLRs), and lipoprotein receptor-related protein 1 (LRP1) appear to influence both the CNS effects of apoE as well as Ab metabolism and toxicity.Therapeutic strategies based on apoE and apoE receptors may include influencing apoE/Ab interactions, apoE structure, apoE lipidation, LDLR receptor family member function, and signaling.Understanding the normal and disease-related biology connecting apoE, apoE receptors, and AD is likely to provide novel insights into AD pathogenesis and treatment.A lzheimer disease (AD), specifically the late- onset form of AD (LOAD), is the most common cause of dementia in individuals older than 60 years of age.Although mutations in the genes PS1, PS2, and APP cause less common forms of early-onset, autosomal dominant familial AD (FAD), these cases represent ,1% of AD.In addition to the genes that cause FAD, LOAD also has a strong genetic component.Although several susceptibility genes for AD have been reported, by far the strongest genetic risk factor for LOAD is apolipoprotein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those who inherit one copy of the e4 form have about three times the risk of developing Alzheimer's compared with those with two copies of the e3 form, while those who inherit two copies of the e4 form have an estimated eight-to 12-fold risk.[73][74][75]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, LDLR and LRP1 disruption by PCSK9 may be crucial for AD progression since they are the major ApoE receptors in the brain, are involved in lipid homeostasis and intracellular signaling, and are fundamental for the regulation of neuronal structure and synaptogenesis [79].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE isoforms may differentially regulate brain lipid metabolism in AD and primary tauopathies.1”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the ε4 allele increases disease risk by approximately four-fold while two copies of the allele increase disease risk by approximately twelvefold relative to individuals who are ε3/ε3 [1, 4, 5].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the brain most cholesterol is produced de novo by astrocytes, and then transported to neurons and other cells by combining with ApoE, mainly synthesized by astrocytes, to form lipoproteins that are secreted through the ATP-binding cassette (ABC) transporters [9,10].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008;…”
BackgroundRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 3×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“…to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al.…”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“…oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman…”
BackgroundStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 4×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
BackgroundInfluentialApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 17×
“In contrast, apoAI in CNS is derived from the periphery (SorciThomas et al. 1988).”
BackgroundInfluentialShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“…Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al. 2010; Palop and Mucke 2010; Renner et al. 2010; Ronicke et al. 2010) (see Mucke and…”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Ab1-42 oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo e…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Interestingly, single-nucleotide polymorphisms in clusterin have been shown to be a risk factor for AD (Harold et al. 2009; Lambert et al. 2009).”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“1) (Zlokovic 2008).”
Research works printed but not linked: 1
- Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. 1994. Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860 -869.
Cited by
Items 701–800 of 810
Ravindran, F., & Justus Liebig University Giessen (2015) · University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen) · doi:10.22029/jlupub-14170
Genetic Screens in Neurodegeneration
Acevedo‐Arozena, A., & Corrochano, S. (2017) · Wiley eBooks · doi:10.1002/9781118540770.ch1
Identification of functional variants in the Alzheimer’s disease candidate gene ABCA7
Clement, N. S. (2017) · Nottingham ePrints (University of Nottingham)
Building Cognitive Resilience Against Alzheimer’s Disease Through Multilingualism
Costa, S. M. (2017) · UWSpace (University of Waterloo)
Can Exposure to Volatile Anesthetics Be a Tipping Point for AD Susceptible Populations?
Niesman, I. (2017) · Annals of Alzheimer s and Dementia Care · doi:10.17352/aadc.000002
“Therefore, dysfunction in transport, uptake or traffi cking of cholesterol may represent major contributing factors to the development of AD [3-5].”
BackgroundSurgery, Anesthesia, and Risk for the Development of Dementia
Velkers, C. (2018) · QSpace (Queen's University Library)
The role of GPR55 in neuronal and immune cell signalling and function
Haugh, O. (2019) · Arrow@dit (Dublin Institute of Technology)
The interplay between mitochondria-endoplasmic reticulum contacts and Alzheimer’s disease
Leal, N. S., & João, N. (2019) · Figshare · Cited by 1
Genetic manipulation of CNS cholesterol metabolism and its effects on cerebral β-amyloidosis
Winchenbach, J. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7274
Modelling the neurobiology of Alzheimer’s disease in vitro
Muñoz, S. S. (2019) · Research Online (University of Wollongong)
A study of the global effects of Apolipoprotein E using lipidomics
Hawksworth, J. I. (2019) · ORCA Online Research @Cardiff (Cardiff University)
Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer’s Disease
Talegaonkar, S., Gautam, N., Varshney, V., Sharma, S., & Bhattacharyya, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_13
Yung, A. (2019) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Tau proteolysis mechanisms and relevance for tauopathies
Quinn, J. P. (2019) · Research Explorer (The University of Manchester)
Isolamento de oligômeros tóxicos do peptídeo B-amiloide usando o anticorpo de cadeia única NUsc1
Bitencourt, A. L. B. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-12022020-170537 · Cited by 1
Markery oxidačního stresu u Alzheimerovy choroby
Caltová, P. (2017) · Digitální knihovna Univerzity Pardubice (Univerzity Pardubice)
Foster, B. M., & Porges, E. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-69892-2_686-1
The interactive impact of omega-3 fatty acids, APOE genotype and sex hormones on cognition
Pontifex, M. G. (2020) · UEA Digital Repository (University of East Anglia) · Cited by 1
Foster, B. M., & Porges, E. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_686
Carrasquillo, M. M., Bu, G., & Nielsen, H. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7309-1_2
Self-citationCellular Mechanisms of Dementia: Animal and Human Studies
Gan, L. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0054
Kipnis, J., & Mesquita, S. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734935594.793556877
Alzheimer’s disease as a syndrome of overloaded amyloidic synaptic tagging in memory networksPreprint
Murphy, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7gsaz
Relationship between platelet indices and lipid status in chronic hookah consumption
Kurtović, A. (2021) · Glasnik hemicara i tehnologa Bosne i Hercegovine · doi:10.35666/2232-7266.2021.56.05
Towairqi, H. A., Alshanqiti, A., Alsaadi, R., & Alhindi, Y. Z. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs221651355
Genome Editing with CRISPR‐Cas Systems
Lotfy, P., & Hsu, P. D. (2022) · Wiley eBooks · doi:10.1002/9781683673798.ch11 · Cited by 1
Li, C., Hou, I., Ma, M., Wang, G., Bai, Y., & Liu, X. (2023) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2023.1122559
“Using little to no prior knowledge, we identified 5 potentially disrupting variants, one of which (C130R) was classified by previous studies as a key risk factor for AD (Holtzman et al., 2012).”
BackgroundGlial Cells in Alzheimer’s Disease: Insights from Patient-Derived Models
Verkerke, M. L. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1838
Alzheimer’s disease beyond the amyloid accumulation
Urkon, M., & Nagy, E. E. (2022) · Orvostudományi Értesítö · doi:10.2478/orvtudert-2022-0002
Immunogenetics of Alzheimer’s disease: the human leukocyte antigen
Costescu, C., Vică, L. M., Bâlici, Ș., Nicula, G. Z., Nemeş, B., Coman, H. G., & Matei, H. V. (2023) · Psihiatru ro · doi:10.26416/psih.75.4.2023.8928
Identifying Alzheimer’s disease-associated genes using PhenoGeneRankerPreprint
Rahman, M. T., Saeed, F., Bozdag, S., & Initiative, A. D. N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.12.623269
Chan, D., Spires‐Jones, T. L., Provenzano, F. A., Glennon, E. B. C., & Duff, K. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780190065324.003.0020
García‐González, P., Puerta, R., Muñoz-Morales, Á., Olivé, C., Calm, B., Montrreal, L., Valenzuela, A., Bayón-Buján, P., Rovira, M., Capdevila-Bayo, M., et al. (2025) · medRxiv · doi:10.1101/2025.03.25.25324541 · Cited by 1
Associations of APOE e2/e4 dosage and lifestyle on neuroimaging markers in the UK BiobankPreprint
Zhang, Y., van der Meer, D., Luykx, J. J., Linden, D. E. J., Rutten, B. P. F., Gülöksüz, S., & Blokland, G. A. M. (2025) · medRxiv · doi:10.1101/2025.05.12.25327420
“The primary function of the APOE gene locus is associated with lipid/cholesterol metabolism, with pleiotropic effects on various biological processes, including neuronal migration, axon guidance, and the clearance of amyloid-𝛽 plaques in the brain — a hallmark of AD pathology [4].”
Genetic Polymorphisms of Apolipoprotein E and Their Impact on Ischemic Stroke Severity and Recovery
Yuan, H., Li, P., & Li, B. (2025) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.70025
“In the central nervous system (CNS), APOE is the primary apolipoprotein synthesized by glial cells and is secreted in the form of HDL-like particles [34].”
黑, 君. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1582260
ApoE4 accelerates the condensate to amyloid transition of tauPreprint
Kumar, V. S. N. R., & Garai, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.22.689889
“These pathways include reduced clearance and enhanced aggregation of Aβ 3–5 , increased tau pathology 6,7 , impaired lipid metabolism 8,9 and synaptic defects 10 , mitochondrial dysfunction 11,12 and exacerbated neuroinflammation 13,14 .”
Simple in vivo models of Alzheimer's disease
Caito, S. W., & Newell-Caito, J. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00006-5
Ibarra-Sánchez, A., Soto-Félix, C., Barraza, L. C., & Sámano, D. B. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/141q5f06
James, K. (2013) · Open University of Cape Town (University of Cape Town)
ApoE4 pathology in Alzheimer's disease from the perspective of organelle dysfunction in astrocytes
Larramona‐Arcas, R., & Molecular, U. A. D. B. D. D. B. I. D. B. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Verelst, J. (2023) · Lirias (KU Leuven)
Molecular mechanisms underlying presenilin-dependent tau pathology in neurodegeneration
Soto-Faguás, C. M. (2021) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Pait, M. C. (2023) · WakeSpace Scholarship (Wake Forest University)
ApoE4 effects on the structural covariance brain networks topology in Mild Cognitive Impairment
Sanabria-Díaz, G. (2021) · IRIS
The cholesteryl transfer protein and apolipoprotein E in Alzheimer's disease models
Efrem, S. (2019) · eScholarship@McGill (McGill) · doi:10.82308/26189
Impacto da exposição do colesterol-LDL nos astrócitos : estudo in vitro e in vivo
Baumart, G. J. (2023) · Lume (Universidade Federal do Rio Grande do Sul)
Vire, J. (2024) · UTUPub (University of Turku)
La théorie d'Hétérochromatine dans le cadre de la maladie d'Alzheimer
Hogan, R. (2022) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/26044
Modulación de los mecanismos de proteólisis como diana terapéutica en la enfermedad del alzheimer
Yamuza Blanco, Á. (2023) · Deposito de Investigacion Universidad de Sevilla (University of Seville)
Using Drosophila melanogaster to model glial lipid biology dysfunction in Alzheimer’s disease
Seliverstov, R. (2024) · ORCA Online Research @Cardiff (Cardiff University)
Donovan, K. W., Stefan, E., Bajrami, B., Bennion, M., Huff, S., Mustafa, D. N., Su, M.-J., Dragan, S., Sciabola, S., Chou, Y.-Y., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2025.12.005
Cruz, L. A., Liu, S., Miskimen, K. L. S., Bailey, J. N. C., Kinzy, T. G., Song, Y. E., Laux, R. A., Miron, P. L., Ogrocki, P. K., Lerner, A. J., et al. (2026) · Annals of Human Genetics · doi:10.64898/2026.01.25.26344754
“APOE normally encodes a product that regulates cholesterol in the brain, and it is known to bind to the A peptide (Holtzman et al., 2012).”
SNP ANALYSIS IN HUMAN ALZHEIMER'S AND PARKINSON'S DISEASES
Siri, G. R., Kumar, D. U., Keerthi, G., & B.Anusha, B. A. (2026) · INTERNATIONAL JOURNAL OF RESEARCH AND ANALYTICAL REVIEWS · doi:10.56975/ijrar.v13i1.327009
ApoE and Methylmercury Intoxication
Bittencourt, L. O., Aschner, M., & Lima, R. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_45-1
The Role of ApoE Genetics in Glial Lipid Metabolism and Inflammation
Julia, T. C. W., Negi, R., & Kurkela, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_74-1
Zhou, X., Wang, R., Yan, J., Wu, X., Yuan, D., Wang, Q., Li, H., & Zhao, W. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026055 · Cited by 1
Park, J. H., Yu, J., Lucey, B. P., & Brubaker, D. K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.21.713391
“Apolipoprotein E e4 (APOE4) is the greatest genetic risk factor, increasing risk by 3x-12x for single or double APOE4 carriers, respectively ( 9 ).”
Chouraki, V. A. (2013) · theses.fr (ABES) · doi:10.70675/3ad681e8z1330z4422zb068zfb803483ea12 · Cited by 2
Rôle de l'apoliprotéine E dans le cycle du virus de l'hépatite C
Lefèvre, M. (2014) · theses.fr (ABES) · doi:10.70675/f91c33acz493dz464bza628zd78da966c293
Fonction des neurotrophines et de la neurotensine dans l'oncogénèse lymphocytaire B
Saada, S. (2015) · theses.fr (ABES) · doi:10.70675/3f4863d1z280az4e70z9199zffb0b80a6f6b
Léger-Charnay, E. (2019) · theses.fr (ABES) · doi:10.70675/72ca31b1zc2d8z41dbz9f66zcbe3f38a8b4a
“…de voies de signalisation, 2) Un domaine transmembranaire, 3) Au moins un domaine EGFP contenant des structures tertiaires β-propeller, permettant une rupture de la liaison récepteur/ligand à un pH acide, 4) un ou plusieurs domaines de liaison au ligand (Holtzman et al., 2012, Go et Mani., 2012).”
BackgroundOméga 3 et troubles de l'humeur : mécanismes d'actions neuroprotecteurs
Martinat, M. (2022) · theses.fr (ABES) · doi:10.70675/6f114f20z6c83z41a1zaa52zb4bae73f6832
Schmidt-Morgenroth, I. (2023) · theses.fr (ABES) · doi:10.70675/f89a7c1ez54acz49f7zbb58z4be7d3ab8c1f
Effets de PCSK9 sur l'allergie
Lorant, V. (2023) · theses.fr (ABES) · doi:10.70675/167b7030z0433z4ddaz899bz309566978a8a · Cited by 1
Various Immunotherapy and Targeted Therapeutics for Managing Alzheimer’s Disease
Verma, M., & Singh, N. K. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010010
CAR-A astrocytes for Alzheimer’s: Promise and challenge
Lee, S.-I., Luo, W., & Gan, L. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.04.008
Saraceno, G. F., Sorrenti, D., Ferraro, C., & Cione, E. (2026) · BioMedInformatics · doi:10.3390/biomedinformatics6030029
“Extensive evidence from human studies and transgenic animal models indicates that ApoE isoforms differentially influence cerebral amyloid burden and disease progression [3,4].”
ApoE and Methylmercury Intoxication
Bittencourt, L. O., Aschner, M., & Lima, R. R. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_45
Mahley, R. W. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_2
The Role of ApoE Genetics in Glial Lipid Metabolism and Inflammation
Julia, T. C. W., Negi, R., & Kurkela, M. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_74
An aging hallmark, Alzheimer's disease, and APOE nexus
Gabrielli, A. P., Weidling, I. W., Lysaker, C. R., Novikova, L., Ranjan, A., Wang, X., Wilkins, H., & Swerdlow, R. H. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261452598
Kortmann, E., Steinacker, P., Guthknecht, A., Barba, L., & Otto, M. (2026) · Journal of Neurochemistry · doi:10.21203/rs.3.rs-9620951/v1
Gillet, J.-N. (2026) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2026.2671163
“…computational scores can invert biological reality and generate classifications that contradict decades of structural, biochemical, and epidemiological evidence (Belloy et al., 2019; Chen et al., 2011; Frieden & Garai, 2012; Hatters et al., 2005; Holtzman et al., 2012; Yamazaki et al., 2019).”
Exploring ceramide as a novel biomarker and therapeutic target for Alzheimer’s disease
Zhao, W., Liu, X., Yao, Y., Yu, Y., & Hu, Z. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1771302 · Cited by 1
“Excessive Cer16:0 and Cer18:0 not only serve as intracellular second messengers but also strongly drive a feed-forward inflammatory cascade by activating the transcription factor NF-κ B (Holtzman et al., 2012).”
Czaniera, N. J., Schulten, W., Nowak, K., Pschik, D., Joneleit, J., Kaltschmidt, B., & Kaltschmidt, C. (2026) · Cells · doi:10.3390/cells15121057
“This structural difference contributes to functional alterations, including changes in lipid transport and a shift towards amyloid-β – related pathways [12–14].”
Ren, L., Luo, X.-Q., Mi, F., & Yu, C. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.06.009
Recent advances in brain aging and epigenetics
Hong-Da, L. I. U., ZHANG, J., & Qiang, L. I. U. (2026) · Shengming kexue · doi:10.3724/cbls.2026086
Cholesterol at the Center of Alzheimer’s Disease: A Unifying Hypothesis on the Pathogenic Mechanism
Zhu, B. T. (2026) · Molecules · doi:10.3390/molecules31142418
Liao, W., Ren, J., Rong, Y., Xie, C., & Yang, X. (2026) · Neuroscience Letters · doi:10.1016/j.neulet.2026.138684
Role of Amyloid Beta and Tau Protein in Alzheimer’s disease
Lodhi, R., & Sharma, V. K. (2026) · Journal of Pharmacy Practice and Community Medicine · doi:10.5530/jppcm.20260040
Lu, Q.-X., & Guan, W. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118316
Nakahara, M., Kataoka, K., Maruyama, T., Nurhamim, M., Zhang, Y., Fukuhara, D., Uchida‐Fukuhara, Y., Islam, M. M., Morita, M., Saito, T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177542
“Alzheimer’s disease (AD) is the most common cause of dementia [1,2].”
You, Y., Lyall, L. M., Ho, F. K. W., Hastie, C. E., & Lyall, D. M. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70470
Estrogen deprivation exacerbates Alzheimer’s disease pathology through neuronal CTSS signaling
Yang, R., Shao, L., Huang, F., He, Y., Yuan, M., Wu, Q., Lin, S., Guo, K., & Zhang, H. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03970-5
“…amyloid models, Apoe is a critical facilitator of fibrillar Aβ depo-sition—genetic reduction of Apoe markedly decreases plaque burden—so an increase in Apoe is expected to promote, rather than mitigate, amyloid accumulation, consistent with the worsened pathology we observed after OVX [48, 49].”
Metadata
- Authors
- Holtzman, D. M., Herz, J., & Bu, G.
- Affiliations
- Washington University in St. Louis (US)
- The University of Texas at Dallas (US)
- Mayo Clinic in Florida (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-01-10
- Volume
- 2
- Issue
- 3
- Pages
- a006312-a006312
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282491
- OpenAlex
- W2143955562
- Cited by
- 782
- References
- 227
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 39 · 2023: 51 · 2022: 76 · 2021: 79 · 2020: 67 · 2019: 66 · 2018: 51 · 2017: 51 · 2016: 60 · 2015: 42 · 2014: 59 · 2013: 41 · 2012: 14
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG030128, R01AG027924, R01AG031784, R01AG035355)
- National Heart, Lung, and Blood Institute (R37HL063762)
- National Institute of Neurological Disorders and Stroke (R37NS034467, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE isoforms, Alzheimer's disease, APOE ε4, APOE2, apoE receptors, low-density lipoprotein receptor family, ApoER2, VLDLR, LRP1, amyloid-beta, amyloid-beta aggregation, amyloid-beta clearance, lipid modification, synaptic plasticity, neuroinflammation, lipid transport, genetic risk factors, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Carrier Proteins, Humans, Neuronal Plasticity, Phosphorylation, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Protein Transport, Low Density Lipoprotein Receptor-Related Protein-1, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.